As of June 21, 2025, Midatech Pharma PLC (MTPH.L) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Midatech Pharma PLC's Forward P/E to Peers
To better understand Midatech Pharma PLC's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Midatech Pharma PLC (MTPH.L) | - |
| Abcam PLC (ABC.L) | 4124.15 |
| Genus PLC (GNS.L) | 2567.42 |
| Sprint Bioscience AB (SPRINT.ST) | 0.88 |
Compared to its competitors, Midatech Pharma PLC's Forward P/E is difficult to compare due to insufficient data.